Daliresp Tablet
Product Images NDC 0310-0095

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Daliresp (NDC 0310-0095). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Dal00 0006 01)

Structural Formula (Dal00 0006 01)
Chemical structure diagram of roflumilast, showing its molecular framework including fluorine, chlorine, and oxygen atoms, consistent with its designation as the active ingredient in Daliresp tablets.*
FDA Label Image

Daliresp 500 Mcg 30 Count Tablets

Daliresp 500 Mcg 30 Count Tablets
Label for Daliresp (roflumilast) tablets, 500 mcg per tablet. The label indicates a package of 30 tablets with a prescription-only designation. Manufactured for AstraZeneca Pharmaceuticals LP, it includes instructions to dispense the accompanying Medication Guide. The label shows the NDC 0310-0095-30 and mentions manufacturing and packaging information with AstraZeneca branding.*
FDA Label Image

Dalriesp 250 Mcg 28 Day Pack

Dalriesp 250 Mcg 28 Day Pack
Daliresp (roflumilast) tablets 250 mcg packaging label showing a 28-day pack with 28 tablets in a child-resistant package. The label displays the product name, strength, form, quantity, and AstraZeneca as the labeler, along with the National Drug Code (NDC).*
FDA Label Image

Figure 1

Figure 1
A scatter plot chart showing fold changes in Cmax and AUC of roflumilast and its N-oxide metabolite relative to a reference when coadministered with various drugs. The drugs are listed vertically with corresponding data points and 90% confidence intervals. Recommendations range from 'Use With Caution' to 'No Dose Adjustment' and 'Not Recommended', based on the observed pharmacokinetic changes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.